Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide.

Moldovan Loomis C, Dutzar B, Ojala EW, Hendrix L, Karasek C, Scalley-Kim M, Mulligan J, Fan P, Billgren J, Rubin V, Boshaw H, Kwon G, Marzolf S, Stewart E, Jurchen D, Pederson SM, Perrino McCulloch L, Baker B, Cady RK, Latham JA, Allison D, Garcia-Martinez LF.

J Pharmacol Exp Ther. 2019 Apr;369(1):26-36. doi: 10.1124/jpet.118.253443. Epub 2019 Jan 14.

PMID:
30643015
2.

A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.

Munjal S, Brand-Schieber E, Allenby K, Spierings ELH, Cady RK, Rapoport AM.

J Headache Pain. 2017 Dec;18(1):31. doi: 10.1186/s10194-017-0740-3. Epub 2017 Mar 1.

3.
4.

Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study.

Silberstein SD, Calhoun AH, Lipton RB, Grosberg BM, Cady RK, Dorlas S, Simmons KA, Mullin C, Liebler EJ, Goadsby PJ, Saper JR; EVENT Study Group.

Neurology. 2016 Aug 2;87(5):529-38. doi: 10.1212/WNL.0000000000002918. Epub 2016 Jul 13.

5.

Managing migraine by patient profile: role of frovatriptan.

Cady RK, Farmer K.

Patient Prefer Adherence. 2016 Apr 5;10:501-10. doi: 10.2147/PPA.S85795. eCollection 2016. Review.

6.

AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.

Tepper SJ, Cady RK, Silberstein S, Messina J, Mahmoud RA, Djupesland PG, Shin P, Siffert J.

Headache. 2015 May;55(5):621-35. doi: 10.1111/head.12583. Epub 2015 May 4.

7.
8.

Acupuncture in the treatment of headache: a traditional explanation of an ancient art.

Cady RK, Farmer K.

Headache. 2015 Mar;55(3):457-64. doi: 10.1111/head.12523. Epub 2015 Feb 16. Review.

PMID:
25683658
9.

A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).

Cady RK, McAllister PJ, Spierings EL, Messina J, Carothers J, Djupesland PG, Mahmoud RA.

Headache. 2015 Jan;55(1):88-100. doi: 10.1111/head.12472. Epub 2014 Oct 30.

10.

Ophthalmic beta blockers: treatment for acute migraine?

Dexter JK, Cady RK.

Mo Med. 2014 Jul-Aug;111(4):292-3. No abstract available.

11.

Red flags and comfort signs for ominous secondary headaches.

Cady RK.

Otolaryngol Clin North Am. 2014 Apr;47(2):289-99. doi: 10.1016/j.otc.2013.10.010. Epub 2014 Jan 10. Review.

PMID:
24680495
12.

Chronic migraine in women.

Cady RK.

J Fam Pract. 2014 Feb;63(2 Suppl):S46-51. Review.

PMID:
24527485
13.

Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination.

Landy SH, Cady RK, Nelsen A, White J, Runken MC.

Headache. 2014 Apr;54(4):640-54. doi: 10.1111/head.12214. Epub 2013 Sep 19.

PMID:
24102322
14.

OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.

Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.

J Neurol Sci. 2013 Aug 15;331(1-2):48-56. doi: 10.1016/j.jns.2013.05.003. Epub 2013 Jun 19.

PMID:
23790235
15.

Evaluation of sumatriptan-naproxen in the treatment of acute migraine: a placebo-controlled, double-blind, cross-over study assessing cognitive function.

Edwards KR, Rosenthal BL, Farmer KU, Cady RK, Browning R.

Headache. 2013 Apr;53(4):656-64. doi: 10.1111/head.12052. Epub 2013 Feb 13.

PMID:
23406052
16.

Advances in drug development for acute migraine.

Cady RJ, Shade CL, Cady RK.

Drugs. 2012 Dec 3;72(17):2187-205. doi: 10.2165/11641120-000000000-00000.

PMID:
23116251
17.

The development of a survey to measure completeness of response to migraine therapy.

Coon CD, Fehnel SE, Davis KH, Runken MC, Beach ME, Cady RK.

Headache. 2012 Apr;52(4):550-72. doi: 10.1111/j.1526-4610.2012.02099.x.

PMID:
22486740
18.

The bowel and migraine: update on celiac disease and irritable bowel syndrome.

Cady RK, Farmer K, Dexter JK, Hall J.

Curr Pain Headache Rep. 2012 Jun;16(3):278-86. doi: 10.1007/s11916-012-0258-y. Review.

PMID:
22447132
19.

Two center, randomized pilot study of migraine prophylaxis comparing paradigms using pre-emptive frovatriptan or daily topiramate: research and clinical implications.

Cady RK, Voirin J, Farmer K, Browning R, Beach ME, Tarrasch J.

Headache. 2012 May;52(5):749-64. doi: 10.1111/j.1526-4610.2011.02054.x. Epub 2011 Dec 21.

PMID:
22188311
20.

Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis.

Seeburger JL, Cady RK, Winner P, MacGregor A, Valade D, Ge Y, Zhang Y, Hustad CM, Strickler N, Schaefer E, Connor KM, Ho TW.

Headache. 2012 Jan;52(1):57-67. doi: 10.1111/j.1526-4610.2011.02027.x. Epub 2011 Nov 11.

PMID:
22078129
21.

Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence.

Rothrock JF, Cady RK, Aurora SK, Brandes JL, Myers JA, Fox AW, Farr SJ.

Curr Med Res Opin. 2011 Nov;27(11):2185-91. doi: 10.1185/03007995.2011.619177. Epub 2011 Sep 26.

PMID:
21942531
22.

Naming migraine and those who have it.

Young WB, Kempner J, Loder EW, Roberts J, Segal JZ, Solomon M, Cady RK, Janoff L, Sheeler RD, Robert T, Yocum J, Sheftell FD.

Headache. 2012 Feb;52(2):283-91. doi: 10.1111/j.1526-4610.2011.01995.x. Epub 2011 Sep 19.

PMID:
21929663
23.

Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans.

Cady RK, Aurora SK, Brandes JL, Rothrock JF, Myers JA, Fox AW, Farr SJ.

Headache. 2011 Sep;51(8):1202-11. doi: 10.1111/j.1526-4610.2011.01972.x. Epub 2011 Aug 3.

PMID:
21812775
24.

A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic™ M) in the treatment of migraine.

Cady RK, Goldstein J, Nett R, Mitchell R, Beach ME, Browning R.

Headache. 2011 Jul-Aug;51(7):1078-86. doi: 10.1111/j.1526-4610.2011.01910.x. Epub 2011 Jun 1.

PMID:
21631494
25.

Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes.

Cady RK, Diamond ML, Diamond MP, Ballard JE, Lener ME, Dorner DP, Derosier FJ, McDonald SA, White J, Runken MC.

Headache. 2011 May;51(5):664-73. doi: 10.1111/j.1526-4610.2011.01894.x.

PMID:
21521204
26.

A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.

Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU.

Headache. 2011 Jan;51(1):21-32. doi: 10.1111/j.1526-4610.2010.01796.x. Epub 2010 Nov 10.

PMID:
21070228
27.

Total migraine freedom, a potential primary endpoint to assess acute treatment in migraine: comparison to the current FDA requirement using the complete rizatriptan study database.

Rodgers AJ, Hustad CM, Cady RK, Martin VT, Winner P, Ramsey KE, Ho TW.

Headache. 2011 Mar;51(3):356-368. doi: 10.1111/j.1526-4610.2010.01771.x. Epub 2010 Oct 12.

PMID:
21039453
28.

OnabotulinumtoxinA (botulinum toxin type-A) in the prevention of migraine.

Cady RK.

Expert Opin Biol Ther. 2010 Feb;10(2):289-98. doi: 10.1517/14712590903586221. Review.

PMID:
20088719
29.

Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use.

Brandes JL, Cady RK, Freitag FG, Smith TR, Chandler P, Fox AW, Linn L, Farr SJ.

Headache. 2009 Nov-Dec;49(10):1435-44. doi: 10.1111/j.1526-4610.2009.01530.x. Epub 2009 Oct 22.

PMID:
19849720
30.

Expanding access to triptans: assessment of clinical outcome.

Cady RK, Goldstein J, Silberstein S, Juhász M, Ramsey K, Rodgers A, Hustad CM, Ho T.

Headache. 2009 Nov-Dec;49(10):1402-13. doi: 10.1111/j.1526-4610.2009.01532.x. Epub 2009 Oct 8.

PMID:
19817885
31.

Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan.

Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL.

Headache. 2009 Oct;49(9):1258-66. doi: 10.1111/j.1526-4610.2009.01523.x.

PMID:
19788468
32.

Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination.

Cady RK, Banks J, Jones BA, Campbell J.

Curr Med Res Opin. 2009 Nov;25(11):2711-21. doi: 10.1185/03007990903285449.

PMID:
19778164
33.

Sinus problems as a cause of headache refractoriness and migraine chronification.

Cady RK, Schreiber CP.

Curr Pain Headache Rep. 2009 Aug;13(4):319-25. Review.

PMID:
19586597
34.

Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials.

Mannix LK, Martin VT, Cady RK, Diamond ML, Lener SE, White JD, Derosier FJ, McDonald SA.

Obstet Gynecol. 2009 Jul;114(1):106-13. doi: 10.1097/AOG.0b013e3181a98e4d.

PMID:
19546766
35.

Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response.

Cady RK, Martin VT, Géraud G, Rodgers A, Zhang Y, Ho AP, Hustad CM, Ho TP, Connor KM, Ramsey KE.

Headache. 2009 May;49(5):687-96.

PMID:
19472447
36.

The future of migraine: beyond just another pill.

Cady RK.

Mayo Clin Proc. 2009 May;84(5):397-9. doi: 10.1016/S0025-6196(11)60556-9. No abstract available.

37.

Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial.

Cady RK, Mathew N, Diener HC, Hu P, Haas M, Novak GP; Study Group.

Headache. 2009 Feb;49(2):216-26. doi: 10.1111/j.1526-4610.2008.01326.x.

PMID:
19222595
38.

Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention.

Cady RK, Freitag FG, Mathew NT, Elkind AH, Mao L, Fisher AC, Biondi DM, Finlayson G, Greenberg SJ, Hulihan JF.

Headache. 2009 Mar;49(3):350-63. doi: 10.1111/j.1526-4610.2009.01340.x. Epub 2009 Feb 11.

PMID:
19220503
39.

Predictors of adherence to triptans: factors of sustained vs lapsed users.

Cady RK, Maizels M, Reeves DL, Levinson DM, Evans JK.

Headache. 2009 Mar;49(3):386-94. doi: 10.1111/j.1526-4610.2009.01343.x. Epub 2009 Feb 11.

PMID:
19220501
40.

Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan.

Newman LC, Cady RK, Landy S, O'Carroll P, Kwong WJ, Burch SP, Nelsen AC, McDonald SA.

Int J Clin Pract. 2008 Dec;62(12):1889-99. doi: 10.1111/j.1742-1241.2008.01935.x.

41.

GERD prevalence in migraine patients and the implication for acute migraine treatment.

Katić BJ, Golden W, Cady RK, Hu XH.

J Headache Pain. 2009 Feb;10(1):35-43. doi: 10.1007/s10194-008-0083-1. Epub 2008 Nov 14.

42.

Treating an acute attack of migraine.

Cady RK.

Headache. 2008 Oct;48(9):1415-6. doi: 10.1111/j.1526-4610.2008.01278.x. No abstract available.

PMID:
19006560
43.

Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study.

Apostol G, Cady RK, Laforet GA, Robieson WZ, Olson E, Abi-Saab WM, Saltarelli M.

Headache. 2008 Jul;48(7):1012-25.

PMID:
18705027
44.

Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial.

Linder SL, Mathew NT, Cady RK, Finlayson G, Ishkanian G, Lewis DW.

Headache. 2008 Oct;48(9):1326-36. doi: 10.1111/j.1526-4610.2008.01138.x. Epub 2008 May 14.

PMID:
18484981
45.

Healthcare provider-patient communication and migraine assessment: results of the American Migraine Communication Study, phase II.

Hahn SR, Lipton RB, Sheftell FD, Cady RK, Eagan CA, Simons SE, Nelson MR.

Curr Med Res Opin. 2008 Jun;24(6):1711-8. doi: 10.1185/03007990802122388. Epub 2008 May 7.

PMID:
18471346
46.

In-office discussions of migraine: results from the American Migraine Communication Study.

Lipton RB, Hahn SR, Cady RK, Brandes JL, Simons SE, Bain PA, Nelson MR.

J Gen Intern Med. 2008 Aug;23(8):1145-51. doi: 10.1007/s11606-008-0591-3. Epub 2008 May 6.

47.

Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines.

Diamond ML, Cady RK, Mao L, Biondi DM, Finlayson G, Greenberg SJ, Wright P.

Headache. 2008 Feb;48(2):248-58. doi: 10.1111/j.1526-4610.2007.01019.x.

PMID:
18234046
48.
49.

The impact of topiramate on health-related quality of life indicators in chronic migraine.

Dodick DW, Silberstein S, Saper J, Freitag FG, Cady RK, Rapoport AM, Mathew NT, Hulihan J, Crivera C, Rupnow MF, Mao L, Finlayson G, Greenberg SJ.

Headache. 2007 Nov-Dec;47(10):1398-408.

PMID:
18052949
50.

The epidemiology and pathophysiology of migraine.

Cady RK.

Manag Care. 2007 Jul;16(7 Suppl 7):4-9; discussion 15-7. Review. No abstract available.

Supplemental Content

Support Center